You are here

leukemia

Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable

Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable

Forbes

cytokine release syndrome

Flag link:

3 Biotech Stocks With Major Catalysts Incoming

3 Biotech Stocks With Major Catalysts Incoming

Motley Fool

TG Therapeutics

Cara Therapeutics

rheumatoid arthritis

Flag link:

New CAR-T drug for leukemia, while effective, is ‘going to cost a fortune’

New CAR-T drug for leukemia, while effective, is ‘going to cost a fortune’

Stat

Flag link:

Two cancer drug prices have already been hiked by 8% this year

Two cancer drug prices have already been hiked by 8% this year

Marketwatch

Teva Pharmaceutical

Flag link:

Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep

Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep

Endpoints

clinical trials

Flag link:

Pfizer's leukemia drug approved by UK cost watchdog after previous rejection

Pfizer's leukemia drug approved by UK cost watchdog after previous rejection

BioPharma Dive

Flag link:

Pfizer Drug Wins U.K. Support Following Overhaul of Cancer Fund

Pfizer Drug Wins U.K. Support Following Overhaul of Cancer Fund

Bloomberg

Flag link:

Martin Shkreli's Arrest Halts Leukemia Drug Trial

Martin Shkreli's Arrest Halts Leukemia Drug Trial

Fortune

clinical trials

Flag link:

Agios Pharma Plunges 15% Despite Strong Data for Leukemia Drug

Agios Pharma Plunges 15% Despite Strong Data for Leukemia Drug

Barron's

Agios Pharmaceuticals

Flag link:

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

The Street

Kite Therapeutics

Flag link:

MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting

MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting

Yahoo/PR Newswire

chronic lymphocytic leukemia

Flag link:

Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease

Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease

Yahoo/PR Newswire

acute lymphoblastic leukemia

Flag link:

Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting

Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting

Yahoo/BusinessWire

Seattle Genetics

acute lymphoblastic leukemia

non-Hodgkin's lymphoma

diffuse large B-cell lymphoma

Flag link:

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells

TheStreet.com

Agios Pharmaceuticals

Flag link:

Geron Collaborates with J&J for Imetelstat

Geron Collaborates with J&J for Imetelstat

Yahoo/Zacks

acute myelogenous leukemia

myelodysplastic syndrome

Flag link:

The Best Blood Cancer Drug Launch Ever?

The Best Blood Cancer Drug Launch Ever?

Forbes

Flag link:

Novartis apologizes for not disclosing side-effects of leukemia drugs sooner

Novartis apologizes for not disclosing side-effects of leukemia drugs sooner

Reuters

Flag link:

Agios Pharmaceuticals announces AG-221 orphan drug designation

Agios Pharmaceuticals announces AG-221 orphan drug designation

Yahoo/The Fly on the Wall

Agios Pharmaceuticals

acute myelogenous leukemia

Flag link:

Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA

Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA

Yahoo/BusinessWire

acute myeloid leukemia

Flag link:

AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting

AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting

Yahoo/PR NewsWire

chronic lymphocytic leukemia

non-Hodgkin's lymphoma

Flag link:

Pages